{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:07:22Z","timestamp":1788872842756,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81173133"],"award-info":[{"award-number":["81173133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.gene.2014.12.051","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T00:41:09Z","timestamp":1419381669000},"page":"200-207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome"],"prefix":"10.1016","volume":"558","author":[{"given":"Xia-qin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang-ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang-le","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2014.12.051_bb0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/FPC.0b013e3282f70458","article-title":"Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration","volume":"18","author":"Aarnoudse","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.gene.2014.12.051_bb0010","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1161\/01.ATV.0000223867.25324.1a","article-title":"Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel","volume":"26","author":"Angiolillo","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.gene.2014.12.051_bb0015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.gene.2014.12.051_bb0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nm.2281","article-title":"Paraoxonase-1 is a major determinant of clopidogrel efficacy","volume":"17","author":"Bouman","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2014.12.051_bb0025","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel","volume":"5","author":"Brandt","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.gene.2014.12.051_bb0030","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis","volume":"49","author":"Buonamici","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.gene.2014.12.051_bb0035","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/nm.2386","article-title":"Paraoxonase-1 and clopidogrel efficacy","volume":"17","author":"Camps","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2014.12.051_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2014.12.051_bb0045","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2014.12.051_bb0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nm.2367","article-title":"Paraoxonase-1 and clopidogrel efficacy","volume":"17","author":"Cuisset","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2014.12.051_bb0055","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nm.2436","article-title":"Paraoxonase-1 and clopidogrel efficacy","volume":"17","author":"Dansette","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2014.12.051_bb0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.1365-2125.2002.01591.x","article-title":"MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine","volume":"53","author":"Drescher","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.gene.2014.12.051_bb0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","article-title":"Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study","volume":"359","author":"Fellay","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2014.12.051_bb0070","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2007.02722.x","article-title":"Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects","volume":"5","author":"Fontana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.gene.2014.12.051_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchromb.2013.02.031","article-title":"A validated HPLC-MS\/MS assay for quantifying unstable pharmacologically active metabolites of clopidogrel in human plasma: application to a clinical pharmacokinetic study","volume":"926","author":"Furlong","year":"2013","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.gene.2014.12.051_bb0080","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients","volume":"17","author":"Giusti","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.gene.2014.12.051_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/FPC.0b013e328333dafe","article-title":"Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation","volume":"20","author":"Harmsze","year":"2010","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.gene.2014.12.051_bb0090","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/01.ATV.0000148708.44691.27","article-title":"Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP","volume":"25","author":"Hetherington","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.gene.2014.12.051_bb0095","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","article-title":"Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement","volume":"48","author":"Hochholzer","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.gene.2014.12.051_bb0100","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2014.12.051_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2010.05.013","volume":"56","author":"Holmes","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.gene.2014.12.051_bb0110","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.gene.2014.12.051_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchromb.2012.11.005","article-title":"HPLC-MS\/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples","volume":"911","author":"Karazniewicz-Lada","year":"2012","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.gene.2014.12.051_bb0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.gene.2014.12.051_bb0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/clpt.2008.20","article-title":"The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance","volume":"84","author":"Kim","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.gene.2014.12.051_bb0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000346736","article-title":"Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention","volume":"91","author":"Liu","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.gene.2014.12.051_bb0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1253\/circj.72.1165","article-title":"Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel","volume":"72","author":"Malek","year":"2008","journal-title":"Circ. J."},{"key":"10.1016\/j.gene.2014.12.051_bb0140","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2014.12.051_bb0145","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2014.12.051_bb0150","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.2005.02229.x","article-title":"Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver","volume":"59","author":"Owen","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.gene.2014.12.051_bb0155","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/chromsci\/46.10.867","article-title":"Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma","volume":"46","author":"Patel","year":"2008","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.gene.2014.12.051_bb0160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jchromb.2011.11.029","article-title":"A sensitive and rapid ultra HPLC-MS\/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma","volume":"880","author":"Peer","year":"2012","journal-title":"J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.gene.2014.12.051_bb0165","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1124\/dmd.30.11.1288","article-title":"Structure and stereochemistry of the active metabolite of clopidogrel","volume":"30","author":"Pereillo","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.gene.2014.12.051_bb0170","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel","volume":"84","author":"Savi","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.gene.2014.12.051_bb0175","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/bbrc.2001.4816","article-title":"P2y(12), a new platelet ADP receptor, target of clopidogrel","volume":"283","author":"Savi","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.gene.2014.12.051_bb0180","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ihj.2013.02.012","article-title":"Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response","volume":"65","author":"Shalia","year":"2013","journal-title":"Indian Heart J."},{"key":"10.1016\/j.gene.2014.12.051_bb0185","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.gene.2014.12.051_bb0190","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/eurheartj\/ehp041","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention","volume":"30","author":"Sibbing","year":"2009","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.gene.2014.12.051_bb0195","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.gene.2014.12.051_bb0200","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/eurheartj\/ehr155","article-title":"No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting","volume":"32","author":"Sibbing","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.gene.2014.12.051_bb0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2014.12.051_bb0210","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1503\/cmaj.060664","article-title":"Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel","volume":"174","author":"Suh","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.gene.2014.12.051_bb0215","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jpba.2008.08.020","article-title":"Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS\/MS","volume":"48","author":"Takahashi","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.gene.2014.12.051_bb0220","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00228-012-1446-8","article-title":"Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention","volume":"69","author":"Tang","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.gene.2014.12.051_bb0225","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of P-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.gene.2014.12.051_bb0230","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","article-title":"Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents","volume":"51","author":"Trenk","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.gene.2014.12.051_bb0235","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1160\/TH10-09-0582","article-title":"An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma","volume":"105","author":"Tuffal","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.gene.2014.12.051_bb0240","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1538-7836.2008.03050.x","article-title":"The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects","volume":"6","author":"Umemura","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.gene.2014.12.051_bb0245","doi-asserted-by":"crossref","first-page":"482763","DOI":"10.1155\/2014\/482763","article-title":"Association between peak neutrophil count, clopidogrel loading dose, and left ventricular systolic function in patients with primary percutaneous coronary intervention","volume":"2014","author":"Wang","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.gene.2014.12.051_bb0250","first-page":"1026","article-title":"Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients","volume":"67","author":"Yang","year":"2012","journal-title":"Pharmazie"},{"key":"10.1016\/j.gene.2014.12.051_bb0255","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2013.05.006","article-title":"Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients","volume":"132","author":"Zhang","year":"2013","journal-title":"Thromb. Res."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111914014620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111914014620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T19:54:58Z","timestamp":1566158098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111914014620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0378111914014620"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2014.12.051","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic polymorphisms of CYP2C19*2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2014.12.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}